Melanoma addiction to the long non-coding RNA SAMMSON.

Nature 2016 Mar;531(7595):518-22

Laboratory For Molecular Cancer Biology, Center for Human Genetics, KULeuven, Herestraat 49, 3000 Leuven, Belgium.

Focal amplifications of chromosome 3p13-3p14 occur in about 10% of melanomas and are associated with a poor prognosis. The melanoma-specific oncogene MITF resides at the epicentre of this amplicon. However, whether other loci present in this amplicon also contribute to melanomagenesis is unknown. Here we show that the recently annotated long non-coding RNA (lncRNA) gene SAMMSON is consistently co-gained with MITF. In addition, SAMMSON is a target of the lineage-specific transcription factor SOX10 and its expression is detectable in more than 90% of human melanomas. Whereas exogenous SAMMSON increases the clonogenic potential in trans, SAMMSON knockdown drastically decreases the viability of melanoma cells irrespective of their transcriptional cell state and BRAF, NRAS or TP53 mutational status. Moreover, SAMMSON targeting sensitizes melanoma to MAPK-targeting therapeutics both in vitro and in patient-derived xenograft models. Mechanistically, SAMMSON interacts with p32, a master regulator of mitochondrial homeostasis and metabolism, to increase its mitochondrial targeting and pro-oncogenic function. Our results indicate that silencing of the lineage addiction oncogene SAMMSON disrupts vital mitochondrial functions in a cancer-cell-specific manner; this silencing is therefore expected to deliver highly effective and tissue-restricted anti-melanoma therapeutic responses.

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature17161DOI Listing
March 2016
86 Reads

Publication Analysis

Top Keywords

sammson
8
non-coding rna
8
long non-coding
8
nras tp53
4
tp53 mutational
4
mutational status
4
irrespective transcriptional
4
transcriptional cell
4
state braf
4
status sammson
4
braf nras
4
cell state
4
targeting sensitizes
4
therapeutics vitro
4
vitro patient-derived
4
patient-derived xenograft
4
mapk-targeting therapeutics
4
melanoma mapk-targeting
4
cells irrespective
4
sensitizes melanoma
4

Similar Publications